Friday, 13 September 2013

Trial In Progressive MS with Fluoxetine

Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, De Keyser J. The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial. ISRN Neurol. 2013; 2013:370943. doi: 10.1155/2013/37094

Preclinical studies suggest that fluoxetine may have neuroprotective properties. In this pilot study forty-two patients with secondary or primary progressive MS were randomized to receive fluoxetine 20 mg twice daily or placebo for 2 years. Every 3 months the Expanded Disability Status Scale (EDSS), 9-hole peg test (9-HPT) and ambulation index (AI) were assessed. Brain MRI scans, Multiple Sclerosis Functional Composite, Fatigue Impact Scale, Guy's neurological disability Scale and SF-36 were performed at baseline, year 1 and year 2. Seven out of 20 (35%) patients in the fluoxetine group and 7 out of 22 (32%) patients in the placebo group had sustained progression on the EDSS, 9-HPT, or AI at 2 years. No differences were identified between the 2 treatment groups with respect to secondary clinical outcomes and T2 lesion load, grey matter volume and white matter volume. An unanticipated low rate of disability progression in the placebo group decreased the statistical power. At least 200 patients would have been needed to detect a 50% treatment effect. This trial shows that fluoxetine was generally well tolerated, but no assumptions can be made about a possible treatment effect. An adequately powered controlled trial of fluoxetine in progressive MS is still warranted.


Fluoxetine, a selective serotonin reuptake inhibitor, used for the treatment of depression but again like CUPID even people on placebo did better than expected, In Animal Studies the action was due to an anti-inflammatory effect, perhaps rather than overtly neuroprotective. will we see another trial?

3 comments:

  1. Another one bites the dust. I think it shines light on the failure of animal models in MS research. It's a distinctly human disease - combo of genes, EBV infection and Vit d deficiency and gender.

    ReplyDelete
    Replies
    1. This comment has been removed by the author.

      Delete
    2. How does "it shines light on the failure of animal models in MS research"

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.